Development and validation of a 34-analyte urine quantitative LC-MS/MS toxicology panel

Area of Science:

• Clinical Chemistry
• Analytical Chemistry
• Forensic Toxicology

Background:

• Accurate drug testing is crucial for clinical decisions in pain management and emergency medicine.
• Liquid chromatography-tandem mass spectrometry (LC-MS/MS) offers superior sensitivity and specificity compared to immunoassays for drug quantification.
• Existing methods required simplification and analyte expansion for comprehensive urine drug testing.

Purpose of the Study:

• To develop and validate a unified clinical LC-MS/MS toxicology panel.
• To quantify 34 drugs and metabolites in urine specimens.
• To improve workflow efficiency and expand analyte detection capabilities.

Main Methods:

• Development and validation of a clinical LC-MS/MS toxicology panel.
• Combined two previous methods into a single workflow.
• Performed comprehensive validation including matrix effects, analytical measurement range, sensitivity, specificity, precision, stability, accuracy, and hydrolysis efficiency.

Main Results:

• Successfully developed and validated a panel for 34 drugs and metabolites.
• Achieved limits of quantitation ranging from 1-25 ng/mL (lower end) to 2000-5000 ng/mL (upper end).
• The new method simplified workflow and detected analytes not previously available.

Conclusions:

• The developed LC-MS/MS method provides a robust, sensitive, and specific tool for clinical urine drug testing.
• This unified panel enhances diagnostic capabilities and streamlines laboratory operations.
• The validated method supports accurate drug monitoring and clinical decision-making.